Compare Neurocrine Biosciences Inc (NBIX) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Novavax Inc — how do they compare? Neurocrine Biosciences Inc trades at $156 (market cap $16.46B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Neurocrine Biosciences Inc is far larger — about 12.6× Novavax Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | NVAX | |
|---|---|---|
Market Cap | $16.46B | $1.31B |
Sector | Health | Health |
52-Week High | $185.50 | $11.19 |
52-Week Low | $123.10 | $6.22 |
Enterprise Value | $16.48B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
